Skip Navigation

News Videos

  • Watch brief explainer videos focusing on science, research, and advances in cancer, featuring Dana-Farber Cancer Institute doctors and researchers.

  • HPV-related Head and Neck Cancer Research
    A research trial at Dana-Farber Cancer Institute is looking at de-intensification as a possible treatment option for patients diagnosed with HPV-related head and neck cancer. Dr. Robert Haddad explains in this video.

  • Brain Cancer Project: Count Me In
    Count Me In, a non-profit patient-partnered research initiative, has launched the Brain Cancer Project. Stewarded by Dana-Farber Cancer Institute, the Emerson Collective, the Broad Institute of MIT and Harvard, and with the Minderoo Foundation, the Brain Cancer Project is aimed at accelerating discoveries.

  • Bile Duct Cancer: A Patient's Journey
    A bile duct (cholangiocarcinoma) patient and her doctor, Dana-Farber's Douglas Rubinson, MD, detail the ups and downs of her journey as well as the latest research into bile duct cancer.

  • Breast Cancer Research: A Focus on Older Women
    Dr. Eric Winer explains the need for an increased focus on studying older women with breast cancer and why the research pendulum is starting to swing in their direction.

  • Dana-Farber Recognized for Excellence in Nursing Practice
    Dana-Farber Cancer Institute has been awarded Magnet® status from the American Nurses Credentialing Center (ANCC) for the fourth consecutive time. This prestigious designation recognizes excellence in nursing practice and health care delivery and has been awarded to only 8% percent of hospitals in the United States.

  • Managing Cancer Pain in the Face of Substance Use Disorders
    A metastatic breast cancer patient with a history of substance use disorder candidly shares her story and challenges of balancing her past with her need for pain management for her cancer.

  • Advances in Pancreatic Cancer Research
    Dana-Farber's Thomas Abrams, MD, details advances in pancreatic cancer research and treatment options. Learn more about our expertise treating pancreatic cancer at

  • Lymphoma chemotherapy drug also acts as immunotherapy, new research finds
    Dana-Farber researchers find large doses of a 60 year-old chemotherapy drug used in certain lymphomas not only kills cancer cells directly, but also spurs an immune system attack on the cells. David Weinstock, MD, explains the research.

  • Breast Cancer Treatment Options Before Surgery
    Eric Winer, MD, director of Dana-Farber Breast Oncology Program says that breast cancer therapy has changed dramatically during the last 20 years. One big area of change is giving more systemic, medical therapies like chemotherapy or hormonal therapy before breast cancer surgery, rather than after.

  • Prostate Cancer: Research Shows New Treatment Option Offers Improved Survival
    A new option for men with metastatic hormone-sensitive prostate cancer that researchers say is superior to the current standard therapy. Dana-Farber's Christopher Sweeney, MBBS, explains. Research presented at #ASCO19 and published in the New England Journal of Medicine.

  • Count Me In: Patients Partner with Researchers to Study Cancer
    “Count Me In” is a non-profit that offers a new model of patient-partnered research. This video features an interview with Dr. Nikhil Wagle who explains how it's changing how researchers study cancer and how patients can get involved.

  • Vitamin D Benefit in Advanced Colorectal Cancer
    Dana-Farber Cancer Institute researchers say first of its kind study shows high-dose vitamin D benefit in patients with advanced colorectal cancer. Results prompt large phase 3 trial. For more information:

  • Precision Cancer Medicine: Dr. Benjamin Izar Named a ‘NextGen Star’ by AACR
    Unlocking cancer’s mysteries one cell at a time, Dana-Farber’s Dr. Benjamin Izar is being recognized by the American Association for Cancer Research as a ‘NextGen Star’ for his work in precision medicine and understanding a tumor’s unique ecosystem.

  • Kidney Cancer: Immunotherapy Combination Shows Promise
    New hope for kidney cancer patients and it comes in the form of an immunotherapy drug combined with a targeted agent. Dana-Farber Cancer Institute researchers say this drug combination could become a new standard, first-line treatment for patients with metastatic kidney cancer.

  • Low-risk Prostate Cancer Patients Opting for Conservative Approach
    An upsurge in a conservative approach to treating low-risk prostate cancer patients, according to a study led by radiation oncologists from Dana-Farber/Brigham and Women’s Cancer Center. Instead of undergoing surgery or radiation, many men are choosing to be closely monitored by their doctors.

  • Tumor Profiling for Ovarian Cancer: One Woman’s Story
    No two cancers are created equal and that’s why the PROFILE research project launched - to help guide doctors in personalizing treatment for patients. And while every case is different, for one grandmother, the decision to have her tumor profiled was life-changing.

  • Immunotherapy May Be Effective for Triple-negative Breast Cancer
    A recent study shows that for the first time, immunotherapy may be effective for treating triple-negative breast cancer. Dana-Farber Cancer Institute's Dr. Eric Winer explains why this is one of the biggest advances in the treatment of triple-negative breast cancer in years.

  • Dana-Farber Researchers Win Grand Challenge for Colorectal Cancer Research
    A tremendous boost for scientists looking to unlock the secrets of microbiota’s role in colorectal cancer. A research team led by Dana-Farber Cancer Institute’s Dr. Matthew Meyerson and Dr. Wendy Garrett, also of the Harvard T.H. Chan School of Public Health, won Grand Challenge funding from Cancer Research UK in the amount of up to $25 million.

  • Immunotherapy and Bladder Cancer
    Researchers at Dana-Farber Cancer Institute are looking to expand treatment options for bladder cancer patients beyond surgery and chemotherapy. In what’s known as the BLASST trial, they’re adding in immunotherapy before any surgery takes place in muscle-invasive bladder cancer.

  • Personalized Vaccine to be Tested for the First Time in Patients with Kidney Cancer
    Doctors at Dana-Farber Cancer Institute are taking personalized cancer care to the next level, working to develop custom-made vaccines for kidney cancer.

  • Center for Protein Degradation at Dana-Farber
    Dr. Nathanael Gray and Dr. Eric Fischer explain the impact of the new Center for Protein Degradation at Dana-Farber Cancer Institute.

  • Trial Aims to Treat Kidney Cancer Tumor Before Surgery
    A clinical trial is looking at a new way to treat kidney cancer – using drug therapies to treat the tumor first, before surgery - in the hope that the T cells will remember what to do in case any of the cancer comes back.

  • Obesity, Women, and Colorectal Cancer
    Colorectal cancer rates overall are going down, but for one group – younger patients – the opposite is true. And in a study published in JAMA ONCOLOGY, for younger women who are also obese, researchers say they’ve uncovered a worrisome trend.

  • Breaking Down Barriers to Getting a Mammogram
    Mammograms can be the first line of defense in detecting breast cancer - but some women don't get one because they can't get to the doctor. Dana-Farber's Mammography Van aims to eliminate barriers by bringing this life-saving tool directly to women in their communities.

  • Expanded Treatment Options for Acute Myeloid Leukemia (AML)
    For patients diagnosed with acute myeloid leukemia or AML, traditional chemotherapy treatment options can’t be endured by many elderly patients. In a recent study, Dana-Farber Cancer Institute’s Dr. Anthony Letai explains that the drug Venetoclax, combined with another drug, Azacytidine, might offer an effective treatment option that will be easier to tolerate. The FDA recently granted accelerated approval for Venetoclax for such AML patients.

  • Breast Cancer Surgery and Impact on Quality of Life in Young Women
    New research released by Dana-Farber/Brigham and Women's Cancer Center shows more young women with breast cancer opting to have mastectomies even as many experience a persistent decline in their sexual and psychosocial well-being. The findings were just presented at the San Antonio Breast Cancer Symposium.

  • Improving Outcomes for Myeloid Cancers
    Improving outcomes for myeloid cancer patients who undergo stem cell transplantation is a focus of several studies presented by Dana-Farber Cancer Institute scientists at the American Society of Hematology Annual Meeting.

  • Myeloma: Immune Response May Predict Progression
    Before symptoms of multiple myeloma develop, Dana-Farber Cancer Institute researchers say a patient’s risk of progression might be tied to certain precursor conditions. The findings were presented at the American Society of Hematology Annual Meeting.

  • Breakthrough for Young Man Treated for Sickle Cell Disease
    An incredible breakthrough for a young man treated for sickle cell disease at the Dana-Farber/Boston Children’s Cancer and Blood Disorder Center. Doctors announce first success story from a new gene therapy strategy.

  • Ovarian Cancer: Past, Present, Future
    Patients diagnosed 34 years apart share their journey with ovarian cancer - reflecting on advances, similarities, and work that still needs to be done. They're brought together by their efforts for Dana-Farber's Susan F. Smith Center for Women's Cancers Executive Council.

  • Metastatic HPV-linked Head and Neck Cancer Study
    Study findings in metastatic HPV-linked head and neck cancer may help guide treatment. Findings published in JCI Insight show better survival rates for some patients. After analyzing tumor DNA, they found these patients have certain mutations in a particular pathway.

  • Boston News Reporter Opens Up About Breast Cancer
    Boston-based television reporter Kelli O'Hara opens up about her journey with breast cancer, the challenges she's facing as a younger woman balancing career and treatment, and her desire to one day have a family.

  • The Metastatic Prostate Cancer Project - Giving a Voice to Prostate Cancer Patients
    “Count Me In” is a new nonprofit organization aiming to partner patients directly with researchers for a number of cancers, including metastatic prostate cancer. For prostate cancer patients, it’s a way to give a voice to a disease that men typically don’t like to talk about. To learn more:

  • Chemical Biology: Small Molecules Making a Big Impact
    A look inside the growing Chemical Biology program at Dana-Farber Cancer Institute. Program Director Dr. Milka Kostic takes you into the labs where chemists and biologists work side-by-side, making and testing small molecules. They're seeking out what might be driving a cancer tumor and the hope is, these molecules might someday be powerful cancer-fighting drugs.

  • Chemotherapy or No Chemotherapy in Breast Cancer
    New findings announced this year show many women with the most common type of breast cancer can confidently skip chemotherapy. Dr. Eric Winer, chief of Dana-Farber Cancer Institute's Breast Oncology Treatment Center, breaks down what women need to know.

  • Rare Genitourinary Cancer
    Imagine having a cancer so rare, trials don't exist for you. That's been the case for years for patients with certain genitourinary cancers. Now, a first of its kind trial at Dana-Farber Cancer Institute offers a potential turning point and the opportunity to try a promising therapy.

  • Coding for Cancer
    Forget Silicon Valley, these women chose Dana-Farber Cancer Institute, working with some of the top minds in cancer genomics. Oncologists and computational biologists come together to analyze sequenced tumors in the hopes of matching tumors with targeted therapies.

  • Study Aims to Help Breast Cancer Patients Emotionally Recover
    Cancer survivors know the journey doesn’t end when treatment ends. That’s especially true for young breast cancer survivors, who often report feeling isolated and anxious. Doctors at Dana-Farber Cancer Institute are looking at mindfulness meditation and survivorship education as part of the "Pathways to Wellness" study.

  • Diet Linked to Bacteria and Certain Types of Colorectal Cancer
    Dana-Farber Cancer Institute researchers looked at the link between diet, gut-health, and colorectal cancers. They found the risk of certain cancers went up if people were eating diets high in red and processed meat, refined grains, and sugar. The study was published in the October 2018 issue of "Clinical Gastroenterology and Hepatology."

  • New Guidelines for Colorectal Cancer Screening
    Dana-Farber Cancer Institute's Dr. Jeffrey Meyerhardt explains why "45" is the new important age when it comes to getting screened for colorectal cancer.

  • 60-year-old Medical Mystery Surrounding Thalidomide Solved
    More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?

  • Cameron Smith Returns to Dana-Farber
    Forty years after being treated for pediatric cancer, Cameron Smith returned to Dana-Farber in an emotional homecoming, and shared a message of hope. Victoria Warren reports for Dana-Farber Cancer Institute.

  • Request a Publication

    Receive by mail the current issue of a Dana-Farber publication by completing this request form.

  • Dana-Farber Facts 2019

    Dana-Farber Facts

    Find facts, figures, and useful information about Dana-Farber's operations and services, including statistics about outpatient visits, clinical trials, patient volume, financial results, and much more.